
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
With advances in the technologies used in LC-MS-based proteomics workflows, sensitive, reproducible, and efficient single-cell proteomics is now possible. Learn about these advances and how they work in concert to maximize the combination of protein and peptide identifications and sample throughput.







